CY6463 (FORMERLY IW-6463)

Clinical trial design for a Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and CNS activity of CY6463 in participants with Alzheimer’s disease with vascular pathology

Alzheimer's Association International Conference (2021)

Chad Glasser, Jennifer Chickering, Phebe Wilson, Emily Florine, Chris Winrow, Chris Wright

This poster details the clinical trial design of a Phase 2a study of CY6463 in participants with Alzheimer’s disease with vascular pathology (ADv).

Return to Archive
Top